dacarbazine (dtic-dome) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.   NCATS

Chemistry

  • SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
  • InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N
  • Mol. Mass: 182.1832
  • ALogP: 0.07
  • ChEMBL Molecule:
    dacarbazine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$6.7500 - $16.3600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide | 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide | 4-(dimethyltriazeno)imidazole-5-carboxamide | 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide | 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide | 5-(dimethyltriazeno)imidazole-4-carboxamide | biocarbazine | dacarbacine | dacarbazin | dacarbazina | dacarbazine | dacarbazinum | darcabazine | decarbazine | deticene | dic | dtci | dtic | dtic-dome | icdmt

Organizations (232)

Research & Development (227)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (30)

Approved Indications (2)


 

Hodgkin Disease

Melanoma

Experimental Indications - Clinical Trial Phases 1-4 (30)


 

Acne Vulgaris (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoid Tumor (Phase 1)

Colonic Neoplasms (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

HIV Infections (Phase 2)

Hodgkin Disease ()

Immunotherapy (Phase 2)

Kidney Neoplasms (Phase 1)

Leiomyosarcoma (Phase 3)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 3)

Melanoma ()

Mycoses (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Neuroendocrine Tumors (Phase 4)

Neurofibrosarcoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parathyroid Neoplasms (Phase 1)

Sarcoma (Phase 3)

Sarcoma, Alveolar Soft Part (Phase 3)

Sarcoma, Synovial (Phase 3)

Sclerosis (Phase 2)

Skin Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 1)

Solitary Fibrous Tumors (Phase 2)

Thyroid Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 192
  • # of Trial Organizations: 227

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue